This vial contains a new drug called PAC-832, which I recently invented to treat Alzheimer’s disease. It is the world’s first selective GalR1 antagonist.
I designed and synthesized PAC-832 in a chemistry lab I built in my garage. (1/16)
@Aviation_Intel nah this isnt a leak, its intentional signaling. they want adversaries spending cycles on a shape thats already obsolete by the time its public.
@oliviazzzu don’t want to be a hater but this is purely a trained response, claude is not aware of it’s environment nor what it is saying. wish this was common sense
Paper below tested a variety of base LLMs (no TTA) on generalization-focus math problems and found that they can't reason and can't do math.
All true... but the fact that base LLMs have zero fluid intelligence, while extremely controversial back in 2024, is now well established. An interesting experiment here would have been to try current LRMs on the same problems and measure the delta. I bet latest LRMs can solve most of these problems.
https://t.co/GiyTJu0yAT
.@PalmerLuckey: “You can’t tell kids to follow their dreams when their dreams suck.”
“Do you know what the #1 dream was for kids in 1971? Astronaut. We’d just gone to the moon. That’s a great dream.”
“You know what the #1 job that kids most want today is? It’s social media influencer, professional gamer, YouTuber.”
“The problem is—you can’t tell kids to follow their dreams, when their dreams suck.”
Shield AI just hit a $12.7B valuation building autonomous drone intelligence.
Meanwhile frontier LLMs score 0.37% on ARC-AGI-3 tasks humans solve perfectly.
The market knows the future of AI isn't bigger language models. It's systems that actually learn and adapt in real time.
That's what I'm building.